Advertisement

Topics

Latest "Delaware's Partnership to Fight Chronic Disease" News Stories

22:08 EDT 23rd September 2018 | BioPortfolio

Here are the most relevant search results for "Delaware's Partnership to Fight Chronic Disease" found in our extensive news archives from over 250 global news sources.

More Information about Delaware's Partnership to Fight Chronic Disease on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Delaware's Partnership to Fight Chronic Disease for you to read. Along with our medical data and news we also list Delaware's Partnership to Fight Chronic Disease Clinical Trials, which are updated daily. BioPortfolio also has a large database of Delaware's Partnership to Fight Chronic Disease Companies for you to search.

Showing "Delaware Partnership Fight Chronic Disease" News Articles 1–25 of 21,000+

Sunday 23rd September 2018

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2018 [Report Updated: 31032018] Prices from USD $2500

Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2018" provides an overview of Neuroendocrine Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Neuroendocrine Carcinoma. Report includes an overview of trial numbers and their a...


Windsor welcomes international staff in World Alzheimer’s Month – Cambridge Network

Cambridge NetworkWindsor welcomes international staff in World Alzheimer's MonthCambridge NetworkCambridgeshire and Peterborough NHS Foundation Trust's (CPFT's) Windsor Research Unit is leading ground-breaking studies into Alzheimer's Disease, attracting talented health professionals worldwide, and helping patients and carers take part in ...and more

You should be aware of the risk for disease transmission from puppies, including the possibility of exposure to multidrug-resistant pathogens. https://buff.ly/2QOMO0A 

You should be aware of the risk for disease transmission from puppies, including the possibility of exposure to multidrug-resistant pathogens. https://buff.ly/2QOMO0A 


Cardiac Dimensions Announces Positive Late-Breaking Results for Blinded Clinical Trial of Minimally Invasive Heart Failure Treatment

In Randomized Blinded Study, the Carillon Mitral Contour System Catheter-Based Treatment Meets Endpoint for Reduction in Regurgitant Volume Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, announced results of the company’s landmark ...

Marijuana Use in Adults Living with Sickle Cell Disease -- http://ow.ly/EaGY30lVabe pic.twitter.com/PHp6AHIghd

Marijuana Use in Adults Living with Sickle Cell Disease -- http://ow.ly/EaGY30lVabe  pic.twitter.com/PHp6AHIghd

Exposure to Tickborne Relapsing Fever Reported Throughout California

International Study Headed by Union Square Medical Associates Finds Extensive Spread of Lyme-like Bacteria in Golden State. SAN FRANCISCO (PRWEB) September 23, 2018 Exposure to Tickborne Relapsing Fever is widespread in California according to a study published in the prestigious International Journal of General Medicine (https://bit.ly/2prCQWv). The report entitled "Relapsing Fever Borrelia...

Surgery for Chronic Pain: Risky and Costly

(MedPage Today) -- Surgery for chronic pain is a prime example of overutilization of healthcare services

The lawyer who became a scientist to find a cure for her fatal disease https://www.theguardian.com/science/2018/sep/23/fatal-familial-insomnia-fight-sonia-vallabh-and-eric-minikel-prion-disease?CMP=twt_a-science_b-gdnscience …

The lawyer who became a scientist to find a cure for her fatal disease https://www.theguardian.com/science/2018/sep/23/fatal-familial-insomnia-fight-sonia-vallabh-and-eric-minikel-prion-disease?CMP=twt_a-science_b-gdnscience …

Our health system is a sick system

Unhealthy behaviors such as smoking, overeating, or lack of exercise lead to chronic health conditions, and many patients wanting to make positive changes to their health may seek the advice of their doctor to do so. But our insurance payment system works against supporting people when they want to act in a healthy way, and […]

Saturday 22nd September 2018

Medical News Today: Could video games help treat chronic back pain?

A recent study concludes that a special type of video game could be used to successfully reduce chronic low back pain at a patient's home.

Takeda Pharmaceuticals USA Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummaryTakeda Pharmaceuticals USA Inc TPUSA, formerly Takeda Pharmaceuticals North America Inc, a subsidiary of Takeda Pharmaceutical Company Ltd, is a developer, manufacturer and distributor of pharmaceutical drugs. The company's products include pioglitazone and glimepiride, lubiprostone, pioglitazone, pioglitazone and metformin HCl, azilsartan medoxomil, alogliptin, peginesatide, lansoprazole, ...

Studies estimate that 10-20 percent of men with #prostatecancer will develop #CRPC. Be sure to talk to your doctor to learn more about disease progression.pic.twitter.com/EMdJIRREhg

Studies estimate that 10-20 percent of men with #prostatecancer will develop #CRPC. Be sure to talk to your doctor to learn more about disease progression. pic.twitter.com/EMdJIRREhg

Medtronic Presents IN.PACT Global Study Three-Year Data and Total IN.PACT(TM) Imaging and Propensity Analyses

Clinical Evidence Shared at TCT and CIRSE Reaffirm IN.PACT(TM) Admiral(TM) Drug-Coated Balloon as a Primary Therapy to Treat Complex, Real-World Patient Populations SAN DIEGO and LISBON, Portugal - September 22, 2018 - Medtronic plc (NYSE:MDT) data announced today continue to reinforce the safety, durability, and consistency of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) ...

Charles River Laboratories International Inc CRL Medical Equipment Deals and Alliances Profile [Report Updated: 24042018] Prices from USD $250

SummaryCharles River Laboratories International Inc Charles River is a contract research organization CRO that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. The organization also offers clinical, manufacturing and operations and staffing support. It focuses on pro...

La Jolla Pharmaceutical Company LJPC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17042018] Prices from USD $250

SummaryLa Jolla Pharmaceutical Company La Jolla is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The company's major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its clinicalstage investigational product include...

Neurology is viewed as a therapeutic category with a considerable market opportunity given the limited progress over the years in both neurodegenerative and psychiatric diseases. It is well known that Alzheimer’s disease remains a focal point for larger

Neurology is viewed as a therapeutic category with a considerable market opportunity given the limited progress over the years in both neurodegenerative and psychiatric diseases. It is well known that Alzheimer’s disease remains a focal point for larger biopharmas $IBB $SAGE

GS $LOXO expected approval of larotrectinib and emerging regulatory path for -292 set Loxo on a path to meaningful end market sales. However, the collaboration partnership with Bayer puts a constraint on revenue and profits and could be a potential hurdle

GS $LOXO expected approval of larotrectinib and emerging regulatory path for -292 set Loxo on a path to meaningful end market sales. However, the collaboration partnership with Bayer puts a constraint on revenue and profits and could be a potential hurdle for an acquirer.

Wow -leads to an immense economic burden, with comparisons to other notable disease burdens like (1)cancer, which National Cancer institute estimated as a $147B annual expenditure in 2017 2) cardiovascular disease,which American Heart Association estimate

Wow -leads to an immense economic burden, with comparisons to other notable disease burdens like (1)cancer, which National Cancer institute estimated as a $147B annual expenditure in 2017 2) cardiovascular disease,which American Heart Association estimated was a $555B burden 2016 https://twitter.com/tgtxdough/status/1043572180804624386 …

[Articles] Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt–chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-b

The Resolute Onyx stent was non-inferior to Orsiro for a combined safety and efficacy endpoint at 1-year follow-up in allcomers. The low event rate in both groups suggests that both stents are safe, and the very low rate of stent thrombosis in the Resolute Onyx group warrants further clinical investigation.

PCMA’s Merritt Reflects On 15 Years At The Helm Of PBM Advocacy

Outgoing Pharmaceutical Care Management Association chief discusses fight over rebates, future of pharmacy benefit management, opportunities and challenges facing his...   

International Water Foundation One Drop Sets New Record Raising $8. ...

NEW YORK, Sept. 22, 2018 /PRNewswire/ -- International water foundation One Drop, in partnership with Phillips Auction House, is thrilled to announce the success of Read more...

Marijuana Use in Adults Living with Sickle Cell Disease -- http://ow.ly/EaGY30lVabe pic.twitter.com/KwzfuXFp1w

Marijuana Use in Adults Living with Sickle Cell Disease -- http://ow.ly/EaGY30lVabe  pic.twitter.com/KwzfuXFp1w

cbdMD Sponsors Rallycross Driver Steve Arpin at 2018 Nitro World Games

SALT LAKE CITY, Sept. 22, 2018 /PRNewswire/ -- cbdMD's partnership with Global Rallycross (GRC) driver Steve Arpin officially kicks off this weekend at the 3rd Read more...

New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD

Novartis International AG / New analysis of Novartis Phase III brolucizumab (RTH258) data reinforces superior reduction of retinal fluid, a key marker of disease activity in nAMD . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Pre-specified analysis provides insight into maintenance treatment effectiveness ...

At #WCLC2018, we’re making the #science of #lungcancer research more accessible. Here’s a quick guide for the #LCSM community interested in learning how to read a scientific paper about the disease.pic.twitter.com/vL1iL1zXxR

At #WCLC2018, we’re making the #science of #lungcancer research more accessible. Here’s a quick guide for the #LCSM community interested in learning how to read a scientific paper about the disease. pic.twitter.com/vL1iL1zXxR


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks